搜索
 > 【CD40】重组蛋白信息

CD40信息

英文名称:Tumor necrosis factor receptor superfamily member 5
中文名称:肿瘤坏死因子受体超家族成员5
靶点别称:Tumor necrosis factor receptor superfamily member 5,CDw40,TNFRSF5,CD40,CD40L receptor,CD_antigen=CD40,B-cell surface antigen CD40,Bp50
上市药物数量:0
临床药物数量:26
最高研发阶段:临床二期

CD40 分子别名

CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50

CD40 分子背景

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40 参考文献

CD40临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ISF-35 Ad-CD154; Ad-ISF35; ISF-35 临床二期 Memgen LLC 慢性淋巴细胞白血病, 非霍奇金淋巴瘤 详情
APX-005M APX-005; APX-005M; EPI-0050,APX005; APX005M; EPI0050 临床二期 Epitomics, Apexigen 神经胶质瘤, 脑肿瘤, 胃癌, 非小细胞肺癌, 食道癌, 实体瘤, 胰腺癌, 黑色素瘤 详情
FFP-104 FFP-104 临床二期 FF Pharma 克罗恩氏病, 原发性胆汁性肝硬化 详情
CDX-1140 CDX-1140 临床一期 Celldex 实体瘤 详情
Bleselumab ASP-1240; 4D11; ASKP-1240,ASP1240 临床二期 协和发酵工业, 安斯泰来 移植排斥反应 详情
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) 临床一期 贝勒医学院 慢性淋巴细胞白血病
ONCOS-401 ONCOS-401 临床前 Targovax 实体瘤
BMS-986090 BMS-986090; Anti-CD40-dab,BMS986090 临床一期 百时美施贵宝 免疫性疾病 详情
Anti-CD40 ChiLob7/4 (BioNTech) 临床二期 BioNTech 头颈癌, 胰腺癌 详情
CFZ-533 CFZ-533; OM11-62-MF 临床二期 诺华 重症肌无力, 干燥综合征, 类风湿性关节炎, 毒性弥漫性甲状腺肿, 肾移植排斥反应 详情
TNX 100 TNX-100 临床一期 Chiron, Tanox 自身免疫疾病, 移植排斥反应, 克罗恩氏病 详情
ADC-1013 ADC-1013; JNJ-64457107 临床一期 Alligator Bioscience, 杨森 实体瘤 详情
Lucatumumab CHIR-12.12; HCD-122 临床二期 诺华, Xoma 慢性淋巴细胞白血病, 滤泡性淋巴瘤, 多发性骨髓瘤, 淋巴瘤 详情
CD40L-GVAX CD40L-GVAX; GM-CSF/CD40L; GM.CD40L; hCD40L/hGM-CSF 临床二期 University of South Florida, 西比曼生物科技(上海)有限公司 肺癌, 黑色素瘤 详情
FFP 102 PG-102 临床二期 PanGenetics, FF Pharma 银屑病关节炎, 克罗恩氏病 详情
BI-655064 BI-655064 临床二期 勃林格殷格翰, 艾伯维 红斑狼疮性肾炎, 免疫性血小板减少性紫癜, 类风湿性关节炎 详情
ABBV-323 ABBV-323; ABBV323 临床一期 艾伯维 克罗恩氏病 详情
SEA-CD40 SEA-CD40 临床一期 Seattle Genetics 实体瘤, 恶性肿瘤 详情
Dacetuzumab PRO-64553; RG-3636; SGN-14; SGN-40; hu-S2C6,huS2C6 临床二期 Seattle Genetics 弥漫大B细胞淋巴瘤 详情
Selicrelumab RG-7876; RO-7009789,RG7876; RO7009789 临床一期 罗氏 实体瘤, 胰腺癌 详情
Teneliximab BMS-224819 临床二期 百时美施贵宝 移植排斥反应, 类风湿性关节炎
CP-870893 CP-870893 临床一期 辉瑞, 美国国立癌症研究所, H. Lee Moffitt Cancer Center and Research Institute 黑色素瘤 详情
CD40 ligand (Celldex Therapeutics) 临床前 安进, Celldex 病毒感染, 实体瘤, 非霍奇金淋巴瘤, 免疫性疾病, 肾癌, 头颈癌, 癌症
SHR-1704 SHR-1704 临床前 江苏恒瑞 实体瘤, 血液病
MP-0310 MP-0310 临床前 Molecular Partners 癌症
AT-1501 AT-1501 临床一期 ALS Therapy Development Institute, Anelixis Therapeutics 肌萎缩性脊髓侧索硬化症

消息提示

请输入您的联系方式,再点击提交!

确定